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	 This	 study	 documents	 a	 case	 of	MMN	 associated	with	 CLL	 (the	  irst	 in	 the	 literature	 to	 our	
knowledge)	in	which	RTX	induced	a	dramatic,	prompt	and	long-lasting	response.	
	 We	hypothesize	 that	 the	expansion	of	B-cell	 clones	may	be	a	prerequisite	 for	RTX	ef icacy	 in	
dysimmune	neuropathies.	Despite	being	anecdotal,	the	case	we	describe	lends	support	to	this	hypothesis.
Case	Report

















remained	 stable,	 and	 both	 prednisone	 and	 cyclosporine	 had	 been	 tapered	 to	 5	 mg/day	 and	 1.5	
mg/kg/day	respectively.	In	September	2010,	the	patient's	muscle	strength	began	to	deteriorate	again	
and,	 one	month	 later,	 he	was	 admitted	 to	 our	 department.	 He	 showed	 a	 slight/moderate	 disability	
(Rankin	3-4).	The	neurological	examination	revealed	weakness	in	the	proximal	and	distal	muscles	of	the	
upper	and	lower	limbs	(MRC	sum-score	60/90:	left	deltoid	4/5,	right/left	biceps	and	extensor	digitorum	








































titer	 of	 both	 the	 anti-GM1	 IgM	 and	 anti-GD1b	 IgM,	 as	 well	 as	 by	 the	 good	 clinical	 response	 to	
immunomodulating	therapy.	Similarly,	the	effect	of	immunomodulating	treatment	upon	nerve	temporal	
dispersion	has	been	reported	in	one	or	more	nerve	segments	in	eight	of	nine	patients	with	MMN	[19].









	 Since	 the	 introduction	of	 IVIg	 as	  irst-line	 treatment	 for	MMN,	 the	majority	of	MMN	patients	
bene it	from	this	treatment,	which	has	negligible	side	effects	[24].	However,	the	effectiveness	of	IVIg	in	
some	patients	may	decline	over	time	[25].	Cyclophosphamide,	if	necessary	combined	with	IVIg,	is	the	




well	 as	 other	 chronic	 lymphoproliferative	 diseases	 [7,	 9,	 27].	 Recent	 years	 have	witnessed	 growing	
interest	in	the	use	of	RTX	to	treat	autoimmune	neuropathies	related	to	IgM	antibody	anti-gangliosides	or	
glycolipids,	 in	which	autoreactive	B	cells	play	a	 central	 role.	The	ef icacy	of	RTX	however	 remains	a	
controversial	issue	[11,	12].	Rituximab	has	been	reported	to	be	effective	in	some	patients	with	MMN	[11,	
28],	as	well	as	in	small	groups	of	IVIg-resistant	MMN	patients	[14,	29].	Moreover,	RTX	was	effectively	used	













produced	 by	 non-clonal	 B	 cells,	while	 leukemic	 cells	 express	monoclonal	 IgM	 antibodies.	Moreover,	








explain	 the	 therapeutic	 activity	 of	 RTX	 in	 this	 and	 other	 similar	 cases	 of	 Ig-M	 immune-mediated	
neuropathy,	as	well	as	in	other	neurological	disorders	and	autoimmune	cytopenias	associated	with	CLL	
[31,	33,	34].	Noteworthy,	the	comparison	of	IgM	anti-GM1	antibodies	from	patients	with	Guillain-Barré	
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Figure	1:	Clinical	course	described	by	MRC	and	Rankin	Scales,	associated	with	the	anti-GM1	IgM	assays	done	
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